| Genomic correlates of clinical outcome in advanced prostate cancer W Abida, J Cyrta, G Heller, D Prandi, J Armenia, I Coleman, M Cieslik, ... Proceedings of the National Academy of Sciences 116 (23), 11428-11436, 2019 | 1011 | 2019 |
| Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial J Mateo, N Porta, D Bianchini, U McGovern, T Elliott, R Jones, I Syndikus, ... The Lancet Oncology 21 (1), 162-174, 2020 | 558 | 2020 |
| Plasma AR and abiraterone-resistant prostate cancer A Romanel, DG Tandefelt, V Conteduca, A Jayaram, N Casiraghi, ... Science translational medicine 7 (312), 312re10-312re10, 2015 | 453 | 2015 |
| Circulating cell-free DNA to guide prostate cancer treatment with PARP inhibition J Goodall, J Mateo, W Yuan, H Mossop, N Porta, S Miranda, ... Cancer discovery 7 (9), 1006-1017, 2017 | 388 | 2017 |
| Prostate-specific membrane antigen heterogeneity and DNA repair defects in prostate cancer A Paschalis, B Sheehan, R Riisnaes, DN Rodrigues, B Gurel, C Bertan, ... European urology 76 (4), 469-478, 2019 | 342 | 2019 |
| PTEN protein loss and clinical outcome from castration-resistant prostate cancer treated with abiraterone acetate R Ferraldeschi, DN Rodrigues, R Riisnaes, S Miranda, I Figueiredo, ... European urology 67 (4), 795-802, 2015 | 269 | 2015 |
| Genomics of lethal prostate cancer at diagnosis and castration resistance J Mateo, G Seed, C Bertan, P Rescigno, D Dolling, I Figueiredo, ... The Journal of clinical investigation 130 (4), 1743-1751, 2020 | 227 | 2020 |
| Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer DN Rodrigues, P Rescigno, D Liu, W Yuan, S Carreira, MB Lambros, ... The Journal of clinical investigation 128 (10), 4441-4453, 2018 | 204 | 2018 |
| Phase II study of sorafenib in patients with sunitinib-refractory metastatic renal cell cancer G Di Lorenzo, G Cartenì, R Autorino, G Bruni, M Tudini, M Rizzo, M Aieta, ... Journal of Clinical Oncology 27 (27), 4469-4474, 2009 | 169 | 2009 |
| Commensal bacteria promote endocrine resistance in prostate cancer through androgen biosynthesis N Pernigoni, E Zagato, A Calcinotto, M Troiani, RP Mestre, B Calì, ... Science 374 (6564), 216-224, 2021 | 159 | 2021 |
| Analytical validation and clinical qualification of a new immunohistochemical assay for androgen receptor splice variant-7 protein expression in metastatic castration-resistant … J Welti, DN Rodrigues, A Sharp, S Sun, D Lorente, R Riisnaes, ... European urology 70 (4), 599-608, 2016 | 142 | 2016 |
| SPOP-mutated/CHD1-deleted lethal prostate cancer and abiraterone sensitivity G Boysen, DN Rodrigues, P Rescigno, G Seed, D Dolling, R Riisnaes, ... Clinical cancer research 24 (22), 5585-5593, 2018 | 141 | 2018 |
| Clinical outcome of prostate cancer patients with germline DNA repair mutations: retrospective analysis from an international study J Mateo, HH Cheng, H Beltran, D Dolling, W Xu, CC Pritchard, H Mossop, ... European urology 73 (5), 687-693, 2018 | 118 | 2018 |
| CHD1 loss sensitizes prostate cancer to DNA damaging therapy by promoting error-prone double-strand break repair TR Shenoy, G Boysen, MY Wang, QZ Xu, W Guo, FM Koh, C Wang, ... Annals of Oncology 28 (7), 1495-1507, 2017 | 117 | 2017 |
| Single-cell analyses of prostate cancer liquid biopsies acquired by apheresis MB Lambros, G Seed, S Sumanasuriya, V Gil, M Crespo, M Fontes, ... Clinical Cancer Research 24 (22), 5635-5644, 2018 | 108 | 2018 |
| Diffusion-weighted imaging as a treatment response biomarker for evaluating bone metastases in prostate cancer: a pilot study R Perez-Lopez, J Mateo, H Mossop, MD Blackledge, DJ Collins, M Rata, ... Radiology 283 (1), 168-177, 2017 | 105 | 2017 |
| Cisplatin and 5‐fluorouracil in inoperable, stage IV squamous cell carcinoma of the penis G Di Lorenzo, C Buonerba, P Federico, S Perdonà, M Aieta, P Rescigno, ... BJU international 110 (11b), E661-E666, 2012 | 102 | 2012 |
| Phase II study of docetaxel re‐treatment in docetaxel‐pretreated castration‐resistant prostate cancer G Di Lorenzo, C Buonerba, A Faiella, P Rescigno, M Rizzo, R Autorino, ... BJU international 107 (2), 234-239, 2011 | 102 | 2011 |
| Biomarkers associating with PARP inhibitor benefit in prostate cancer in the TOPARP-B trial S Carreira, N Porta, S Arce-Gallego, G Seed, A Llop-Guevara, D Bianchini, ... Cancer discovery 11 (11), 2812-2827, 2021 | 92 | 2021 |
| Paclitaxel in pretreated metastatic penile cancer: final results of a phase 2 study G Di Lorenzo, P Federico, C Buonerba, N Longo, G Cartenì, R Autorino, ... European urology 60 (6), 1280-1284, 2011 | 92 | 2011 |
